Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Novo Nordisk current and future product portfolio covers
the type 2 diabetes treatment cascade¹
Overview of current and future products in Novo Nordisk's diabetes portfolio
When basal insulin is not enough
When
metformin is
not enough
When it's time
for insulin
Once-daily
optimisation
Mealtime insulin control
Slide 44
Second generation
analogues
First generation
analogues
Human insulin
oral semaglutide
OZEMPİC
semaglutide injection
TRESIBA
Xultophy
RYZODEG
Fiasp
fast-acting insulin aspart
or
VICTOZAⓇ
LevemirⓇ
Novo Mix®
Novo Rapid
or
Insulatard®
Mixtard® 30
ActrapidⓇ
1 Pending clinical development programmes and regulatory processes for oral semaglutide and semaglutide
changing
diabetes®
novo nordiskView entire presentation